Literature DB >> 8634710

Structural characterization of the FKHR gene and its rearrangement in alveolar rhabdomyosarcoma.

R J Davis1, J L Bennicelli, R A Macina, L M Nycum, J A Biegel, F G Barr.   

Abstract

The FKHR gene, which contains a forkhead DNA-binding motif, is fused to either PAX3 or PAX7 by the t(2;13) or t(1;13) translocation in alveolar rhabdomyosarcoma,respectively. These tumors express chimeric transcripts encoding the N-terminal portion of either PAX protein fused to the C-terminal portion of FKHR. To understand the structural basis and functional consequences of these translocations, we characterized the wild-type FKHR gene and its rearrangement in alveolar rhabdomyosarcomas. By isolating and analyzing phage, cosmid and YAC clones, we determined that FKHR consists of three exons spanning 140 kb and that several highly similar loci are present in other genomic regions. Exon 1 encodes the N-terminus of the forkhead domain and is embedded within demethylated CpG island. RNA analyses reveal FKHR transcripts initiate from a TATA-less promoter within this island. Exon 2 encodes the C-terminus of the forkhead domain and a transcription activation domain, whereas exon 3 encodes a large 3' untranslated region. The intron 1-exon 2 boundary precisely matches the FHKR fusion point in the chimeric transcripts found in alveolar rhabdomyosarcomas. Using pulsed-field and fluorescence in situ hybridization analyses, we demonstrate that the 130kb FKHR intron 1 is rearranged in t(2;13)-containing alveolar rhabdomyosarcomas. Our findings indicate that FKHR intron 1 provides a large target for DNA rearrangemnt. Rearrangement of this intron with PAX3 produces two important functional consequences: in-frame fusion of N-terminal PAX3 sequences to the FKHR transcriptional activation domain and disruption of the FKHR DNA binding domain.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8634710     DOI: 10.1093/hmg/4.12.2355

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  9 in total

Review 1.  The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation.

Authors:  Lars P Van Der Heide; Marco F M Hoekman; Marten P Smidt
Journal:  Biochem J       Date:  2004-06-01       Impact factor: 3.857

2.  Targeted polytherapy in small cell sarcoma and its association with doxorubicin.

Authors:  S N Dumont; D Yang; A G Dumont; D Reynoso; J-Y Blay; J C Trent
Journal:  Mol Oncol       Date:  2014-06-10       Impact factor: 6.603

3.  A splice junction-targeted CRISPR approach (spJCRISPR) reveals human FOXO3B to be a protein-coding gene.

Authors:  Evan E Santo; Jihye Paik
Journal:  Gene       Date:  2018-06-18       Impact factor: 3.688

Review 4.  Cell lineage and cell death: Caenorhabditis elegans and cancer research.

Authors:  Malia B Potts; Scott Cameron
Journal:  Nat Rev Cancer       Date:  2010-12-02       Impact factor: 60.716

Review 5.  Pigmentation PAX-ways: the role of Pax3 in melanogenesis, melanocyte stem cell maintenance, and disease.

Authors:  Jennifer D Kubic; Kacey P Young; Rebecca S Plummer; Anton E Ludvik; Deborah Lang
Journal:  Pigment Cell Melanoma Res       Date:  2008-12       Impact factor: 4.693

Review 6.  Pediatric Rhabdomyosarcoma.

Authors:  Jack F Shern; Marielle E Yohe; Javed Khan
Journal:  Crit Rev Oncog       Date:  2015

Review 7.  Current and Future Treatment Strategies for Rhabdomyosarcoma.

Authors:  Celine Chen; Heathcliff Dorado Garcia; Monika Scheer; Anton G Henssen
Journal:  Front Oncol       Date:  2019-12-20       Impact factor: 6.244

8.  Aberrant over-expression of a forkhead family member, FOXO1A, in a brain tumor cell line.

Authors:  Peter B Dallas; Simone Egli; Philippa A Terry; Ursula R Kees
Journal:  BMC Cancer       Date:  2007-04-19       Impact factor: 4.430

9.  Akt-induced phosphorylation of N-CoR at serine 1450 contributes to its misfolded conformational dependent loss (MCDL) in acute myeloid leukemia of the M5 subtype.

Authors:  Dawn Sijin Nin; Azhar Bin Ali; Koichi Okumura; Norio Asou; Chien-Shing Chen; Wee Joo Chng; Matiullah Khan
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.